Alexion
121 Seaport Blvd Boston
Boston
MA
02210
United States
Tel: 475-230-2596
Website: http://www.alexion.com/
735 articles about Alexion
-
Alexion Pharmaceuticals Inc. Release: Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of Patients With PNH at the American Society of Hematology Annual Meeting
11/11/2009
-
Alexion Pharmaceuticals Inc. to Present at Credit Suisseās 2009 Healthcare Conference
11/5/2009
-
Alexion Pharmaceuticals Inc. to Present at the Oppenheimer 20th Annual Healthcare Conference
10/28/2009
-
Alexion Pharmaceuticals Inc. Reports Third Quarter 2009 Results
10/22/2009
-
Alexion Pharmaceuticals Inc. Q3 Results Beat Street, Raises FY View
10/22/2009
-
Alexion Pharmaceuticals Inc. to Report Third Quarter 2009 Results on October 22, 2009
10/12/2009
-
Alexion Pharmaceuticals Inc. to Present at the UBS Global Life Sciences Conference
9/16/2009
-
European Commission and U.S. FDA Grant Alexion Pharmaceuticals Inc.'s Soliris(R) (eculizumab) Orphan Drug Designation for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS)
8/6/2009
-
Alexion Pharmaceuticals Inc.'s Soliris(TM) (Eculizumab), The First and Only Therapy For The Treatment of Patients with PNH, Is Now Available in Canada
8/6/2009
-
Alexion Pharmaceuticals Inc. Reports Second Quarter 2009 Results
7/23/2009
-
Alexion Pharmaceuticals Inc. Q2 Profit Beats Street, Raises FY 2009 Outlook
7/23/2009
-
Alexion Pharmaceuticals Inc. to Report Second Quarter 2009 Results on July 23, 2009
7/9/2009
-
Alexion Pharmaceuticals Inc. Extends Its Commitment to a Green Footprint Through Its Ambitious New Solar Energy System
6/19/2009
-
Alexion Pharmaceuticals Inc.'s Soliris(R) Receives 2009 Prix Galien France for Most Innovative Drug for Rare Disease
6/10/2009
-
Alexion Pharmaceuticals Inc. to Present at the Jefferies & Co. 3rd Annual Healthcare Conference
6/10/2009
-
Alexion Pharmaceuticals Inc. to Present at Investor Conferences
6/3/2009
-
Alexion Pharmaceuticals Inc. Results: New Study Results Verify That PNH Cells Are Found in Majority of Patients with Bone Marrow Failure Syndromes
5/29/2009
-
Researchers to Report on the Investigational Use of Alexion Pharmaceuticals Inc.'s Soliris(R) (Eculizumab) to Prevent Antibody-Mediated Rejection in High-Risk Kidney Transplant Patients
5/28/2009
-
Alexion Pharmaceuticals Inc. Reports First Quarter 2009 Results
4/23/2009
-
Alexion Pharmaceuticals Inc. Q1 Profit Beats Street on Higher Soliris Sales
4/23/2009